Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2024-12-26 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司关于实际控制人所持有的部分股份第二次司法拍卖结果的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the results of a judicial auction of shares held by the actual controller of the company, which may lead to a change in the actual controller. It details the auction process, the winning bidder, the number of shares involved, and the potential impact on control of the company. There are no financial statements, management discussion, or detailed financial data. The document is a regulatory announcement about a significant shareholding change due to a judicial auction, not a financial report or earnings release. This fits best under Major Shareholding Notification (MRQ) as it informs about a change in significant share ownership levels.
2024-12-26 Chinese
江苏四环生物股份有限公司关于子公司被纳入失信被执行人名单的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement by Jiangsu Sihuan Bio Co., Ltd. regarding its subsidiary being listed as a dishonest executor by a court due to unpaid debts. It details the legal case, the obligations, and the impact on the company. The document is short (1061 characters) and focuses on a legal proceeding update rather than financial results, management changes, or shareholder votes. It does not contain financial statements or detailed financial data. It is not an annual or interim report, earnings release, or management discussion. It is not a certification or a report publication announcement. The content fits best under Legal Proceedings Report (LTR) as it updates on a significant legal matter involving the company.
2024-12-13 Chinese
江苏四环生物股份有限公司关于实际控制人所持有的部分股份被第二次司法拍卖的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Sihuan Bio Co., Ltd. regarding the judicial auction of shares held by the actual controller. It details the auction dates, share quantities, and potential impact on company control. The text is an official notice about a legal/financial event affecting shareholding but does not contain financial statements, management discussion, or detailed financial data. It is not a report but an announcement of a significant event related to shareholding and control. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about a judicial auction and potential control change, without being a full financial report or other specific filing type.
2024-12-10 Chinese
江苏四环生物股份有限公司关于实际控制人所持有的部分股份被司法拍卖的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the judicial auction progress of shares held by the actual controller. It details the auction results, the number of shares involved, and the impact on the company. The document is short (1126 characters) and focuses on a specific event related to shareholding and legal proceedings rather than a financial report or detailed management discussion. It does not contain financial statements or detailed financial data. The content fits best under a Regulatory Filings (RNS) category as it is a regulatory announcement about shareholding and legal auction progress, not a full report or financial disclosure.
2024-12-06 Chinese
江苏四环生物股份有限公司关于实际控制人被司法拍卖的部分股份完成过户暨被动减持的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a judicial auction and transfer of shares held by the actual controller of the company, including details of shareholding changes and risk warnings. It does not contain financial statements, management discussion, or detailed financial data. The document is a regulatory announcement about shareholding changes due to judicial auction and passive reduction, not a full financial report or earnings release. Therefore, it fits best under the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2024-11-28 Chinese
江苏四环生物股份有限公司关于变更签字注册会计师的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the change of the signing certified public accountant for the company's 2024 financial audit. It details the replacement of one signing CPA with another due to rotation rules, and confirms that this change will not affect the 2024 financial statements or internal control audit work. The document is short (933 characters) and focuses on the change of auditors rather than presenting any audit report or financial data. It is not a full audit report, nor an annual or interim report. It is a regulatory announcement about audit personnel changes, which fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full report itself. The document is not a mere publication announcement or certification letter, so it is not RPA or RNS. Therefore, the classification is AR with high confidence. FY 2024
2024-11-27 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.